Does KRAS Testing in Metastatic Colorectal Cancer Impact Overall Survival? A Comparative Effectiveness Study in a Population-Based Sample

PURPOSE: Epidermal growth factor receptor (EGFR) inhibitors are approved for treating metastatic colorectal cancer (CRC); KRAS mutation testing is recommended prior to treatment. We conducted a non-inferiority analysis to examine whether KRAS testing has impacted survival in CRC patients. PATIENTS A...

Descripción completa

Detalles Bibliográficos
Autores principales: Feigelson, Heather Spencer, Zeng, Chan, Pawloski, Pamala A., Onitilo, Adedayo A., Richards, C. Sue, Johnson, Monique A., Kauffman, Tia L., Webster, Jennifer, Nyirenda, Carsie, Alexander, Gwen L., Hwang, Clara, Cross, Deanna, McCarty, Catherine A., Davis, Robert L., Schwarzkopf, Denise, Williams, Andrew E., Honda, Stacey, Daida, Yihe, Kushi, Lawrence H., Delate, Thomas, Goddard, Katrina A. B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4006772/
https://www.ncbi.nlm.nih.gov/pubmed/24788807
http://dx.doi.org/10.1371/journal.pone.0094977

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4006772/
https://www.ncbi.nlm.nih.gov/pubmed/24788807
http://dx.doi.org/10.1371/journal.pone.0094977

Ejemplares similares